Thermo Fisher Scientific Phospho-Lck (Tyr505) Recombinant Rabbit Monoclonal Antibody (LckY505-A3)

Applications

Tested Dilution

Publications

Western Blot (WB)

Assay-dependent

-

Flow Cytometry (Flow)

1-1,000 ng/mL

-

Product Specifications

Species Reactivity

Human

Host/Isotype

Rabbit / IgG, kappa

Expression System

HEK293 cells

Class

Recombinant Monoclonal

Type

Antibody

Clone

LckY505-A3

Immunogen

A synthetic phospho-peptide corresponding to residues surrounding Tyr505 of human phospho Lck.

Conjugate

Unconjugated Unconjugated Unconjugated

View additional formats

• APC
• FITC
• PE
• Request custom conjugation

Form

Liquid

Concentration

0.5 mg/mL

Purification

Protein A/G

Storage buffer

PBS, pH 7.4, with 0.1% BSA, 50% glycerol

Contains

0.02% sodium azide

Storage conditions

-20°C

Shipping conditions

Ambient (domestic); Wet ice (international)

RRID

AB_2745025

Product Specific Information

Recombinant rabbit monoclonal antibodies are produced using in vitro expression systems. The expression systems are developed by cloning in the specific antibody DNA sequences from immunoreactive rabbits. Then, individual clones are screened to select the best candidates for production. The advantages of using recombinant rabbit monoclonal antibodies include: better specificity and sensitivity, lot-to-lot consistency, animal origin-free formulations, and broader immunoreactivity to diverse targets due to larger rabbit immune repertoire.

Target Information

LCK is a member of the Src-family tyrosine kinase, which are essential for signaling through the T-cell receptor (TCR) complex. Upon TCR triggering, LCK phosphorylates the ITAM motives in its zeta subunits establishing binding sites for the SH2 domains of the tyrosine kinase ZAP70, which is also phosphorylated by LCK and activated to generate subsequent signaling platforms by phosphorylation of adaptor LAT. The majority of LCK is localized to the plasma membrane, however, there is also a significant fraction associated with the Golgi apparatus which may contribute to Raf activation under conditions of weak stimulation through the TCR. LCK contains N-terminal sites for myristylation and palmitylation, a PTK domain, and SH2 and SH3 domains which are involved in mediating protein-protein interactions with phosphotyrosine-containing and proline-rich motifs, respectively. LCK is also involved in the regulation of apoptosis induced by various stimuli, but not by the death receptors. Diseases associated with LCK include Immunodeficiency 22 and CD45 deficiency. Alternatively splice variants of the LCK gene encoding different isoforms of the protein have been found.

For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.